Fritz Oesterle to retire as Celesio's chairman
This article was originally published in Scrip
Fritz Oesterle, chairman of Celesio's management board, is to retire on 30 June, after the company's supervisory board has approved his amicable and mutual preterm resignation. Mr Oesterle had led Celesio for more than 12 years when he pushed its international expansion as a pharmaceutical wholesaler and retailer, and supported the development of businesses less affected by public health regulations, such as services and logistics for the pharmaceutical industry.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.